The soluble CTLA-4 receptor and its role in autoimmune diseases: An update

Autoimmunity Highlights

Volumn 1, Issue 2, 2010, Pages 73-81

  Saverino, Daniele ^a   Simone, Rita ^a   Bagnasco, Marcello ^b   Pesce, Giampaola ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Autoimmune disease; Ctla 4; Immunoregulation; T cell activation

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ALTERNATIVE RNA SPLICING; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; CELIAC DISEASE; CTLA 4 GENE; CYTOKINE PRODUCTION; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNOREGULATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

EID: 79960064823     PISSN: 20380305     EISSN: 20383274     Source Type: Journal    
DOI: 10.1007/s13317-010-0011-7     Document Type: Article

References (78)

1. Lenschow DJ, Walunas TL, Blueston JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233-258
2. Bocko D, Kosmaczewska A, Ciszak L et al (2002) CD28 costimulatory molecule - expression, structure and function. Arch Immunol Ther Exp 50:169-177
3. Shapiro VS, Truitt KE, Imboden JB et al (1997) CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL- 2B AP-1 sites. Mol Cell Biol 17:4051-4058
4. Walunas TL, Lenschow DJ, Bakker CY et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413
5. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465
6. Saverino D, Tenca C, Zarcone D et al (1999) CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion. J Immunol 162:651-658
7. Merlo A, Tenca C, Fais F et al (2005) Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 12:705-712
8. Laurent S, Carrega P, Saverino D et al CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol. DOI: http://dx.doi.org/10.1016/j. humi -mm.2010.07.007
9. Saverino D, Merlo A, Bruno S et al (2002) Dual effect of CD85/leukocyte Ig-like receptor-1/Ig-like transcript 2 and CD152 (CTLA-4) on cytokine production by antigen-stimulated human T cells. J Immunol 168:207-215
10. Oaks MK, Hallett KM, Penwell RT et al (2000) A native soluble form of CTLA-4. Cell Immunol 201:144-153
11. Simone R, Saverino D (2009) The soluble CTLA-4 receptor and its emerging role in autoimmune diseases. Curr Immunol Rev 5:54-68
12. Wong CK, Lun SWM, Ko FW et al (2005) Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clin Exp Immunol 141:122-129
13. Saverino D, Riccio AM, Rogkakou A et al (2009) Serum CTLA- 4 in Hymenoptera venom allergy end its modulation by specific immunotherapy. J Allergy Clin Immunol 123:258-260
14. Sakthivel P, Wermeling F, Elmgren A et al (2010) Circulating soluble CTLA-4 is related to inflammatory markers in the 70 year old population. Scand J Clin Lab Invest 70:237-243
15. Tunbridge WM, Evered DC, Hall R et al (1997) The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 7:481-493
16. Ueda H, Howson JM, Esposito L et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511
17. Awata T, Kurihara S, Iitaka M et al (1998) Association of CTLA- 4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. Diabetes 47:128-129
18. Kouki T, Sawai Y, Gardine CA et al (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165:6606-6611
19. Mochizuki M, Amemiya S, Kobayashi K et al (2003) Association of the CTLA-4 gene 49 A/G polymorphism with type 1 diabetes and autoimmune thyroid disease in Japanese children. Diabetes Care 26:843-847
20. Oaks MK, Hallett KM (2000) A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 164:5015-5018
21. Lafage-Pochitaloff M, Costello R, Couez D et al (1990) Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34. Immunogenetics 31:198-201
22. Harper K, Balzano C, Rouvier E et al (1991) CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal localization. J Immunol 147:1037-1044
23. Linsley PS, Greene JL, Brady WH et al (1994) Human B.7-1 (CD80) and B.7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793-801
24. Nisticò L, Buzzetti R, Pritchard LE et al (1996) The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Hum Mol Genet 5:1075-1080
25. Deichmann K, Heinzmann A, Brüggenolte et al (1996) An Mse I RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 225:817-818
26. Davies TF (1996) The pathogenesis of Graves' disease. In: Braverman LE, Utiger RD (eds) The thyroid, 7th edn. Lippincott- Raven, Philadelphia, pp 525-536
27. Tomer Y, Huber A (2009) The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun 32:231-239
28. Weetman AP, McGregor AM (1994) Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 15:788-830
29. Yanagawa T, Hidaka Y, Guimaraes V et al (1995) CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 80:41-45
30. Zhao SX, Pan CM, Cao HM et al (2010) Association of the CTLA4 gene with Graves' disease in the Chinese Han population. PLoS One 5:e9821
31. Gu LQ, Zhu W, Zhao SX et al (2010) Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease. Clin Endocrinol 72:248-255
32. Yin X, Latif R, Bahn R et al (2008) Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy. Thyroid 18:1201-1206
33. Daroszewski J, Pawlak E, Karabon L et al (2009) Soluble CTLA- 4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur J Endocrinol 161:787-793
34. Dallos T, Avbelj M, Barák L et al (2008) CTLA-4 gene polymorphisms predispose to autoimmune endocrinopathies but not to celiac disease. Neuro Endocrinol Lett 9:334-340
35. Douroudis K, Prans E, Kisand K et al (2009) Cytotoxic Tlymphocyte antigen 4 gene polymorphisms are associated with latent autoimmune diabetes in adults. Clin Chim Acta 403:226-228
36. Saleh HM, Rohowsky N, Leski M (2008) The CTLA4 -819 C/T and +49 A/G dimorphisms are associated with Type 1 diabetes in Egyptian children. Indian J Hum Genet 14:92-98
37. Kristiansen OP, Larsen ZM, Pociot F (2000) CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun 1:170-184
38. Fritze D, Herrman C, Naeim F et al (1974) HL-A antigens in myasthenia gravis. Lancet 1:240-242
39. Fernández-Mestre M, Sánchez K, Balbás O et al (2009) Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. Hum Immunol 70:532-535
40. Wray BN, Stankovich J, Whittock L et al (2008) CTLA-4 and multiple sclerosis: the A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population. J Neuroimmunol 196:139-142
41. Muñoz-Valle JF, Valle Y, Padilla-Gutiérrez JR et al (2010) The +49A>G CTLA-4 polymorphism is associated with rheumatoid arthritis in Mexican population. Clin Chim Acta 411:725-728
42. Holopainen P, Naluai AT, Moodie S et al; Members of the European Genetics Cluster on Coeliac Disease (2004) Candidate gene region 2q33 in European families with coeliac disease. Tissue Antigens 63:212-222
43. Talwalkar JA, Lindor KD (2003) Primary biliary cirrhosis. Lancet 362:53-61
44. Gershwin ME, Mackay IR (2008) The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47:737-745
45. Invernizzi P, Selmi C, Poli F et al (2008) Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology 48:1906-1912
46. Donaldson PT, Baragiotta A, Heneghan MA et al (2006) HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 44:667-674
47. Shimoda S, Nakamura M, Ishibashi H et al (1995) HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 181:1835-1845
48. Joshita S, Umemura T, Yoshizawa K et al; Shinshu PBC Study Group (2010) Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J Hepatol 53:537-541
49. Saverino D, Brizzolara R, Simone R et al (2007) Soluble CTLA- 4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune esponse dysregulation. Clin Immunol 123:190-198
50. Wang XB, Kakoulidou M, Giscombe R et al (2002) Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 130:224-232
51. Simone R, Brizzolara R, Chiappori A et al (2009) A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury and tTG antibody production. Int Immunol 21:1037-1045
52. Wang XB, Giscombe R, Yan Z et al (2002) Expression of CTLA- 4 by human monocytes. Scand J Immunol 55:53-60
53. Liu MF, Wang CR, Chen PC et al (2003) Increased of expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol 57:568-572
54. Sato S, Fujimoto M, Hasegawa M et al (2004) Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology 43:1261-1266
55. Wong CK, Lit LCW, Tam LS et al (2005) Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 44:989-994
56. Bergholdt R, Taxvig C, Eising S et al (2005) BLB variants in type 1 diabetes and their genetic interaction with CTLA4. J Leukoc Biol 77:579-585
57. Brunet JF, Denizot F, Luciani MF et al (1987) A new member of the immunoglobulin superfamily - CTLA-4. Nature 328:267-270
58. Dariavach P, Mattei MG, Golstein P et al (1988) Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human cytoplasmic domains. Eur J Immunol 18:1901-1905
59. Ligers A, Xu C, Saarinen S et al (1999) The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 97:182-190
60. Toussirot E, Saas P, Deschamps M et al (2009) Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Res Ther 11:R101
61. Tector M, Khatri BO, Kozinski K et al (2009) Biochemical analysis of CTLA-4 immunoreactive material from human blood. BMC Immunol 10:51-60
62. Umemura T, Ota M, Hamano H et al (2008) Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol 103:588-594
63. Lowe RM, Graham J, Sund G et al (2000) The length of the CTLA-4 microsatellite (AT)N-repeat affects the risk for type 1 diabetes. Autoimmunity 32:173-180
64. Chang M-C, Chang Y-T, Tien Y-W et al (2007) T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clin Chemi 53:1700-1705
65. Grohmann U, Orabona C, Fallarino F et al (2002) CTLA-4-Ig regulates catabolism in vivo. Nat Immunol 3:1097-1101
66. Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20:469-473
67. Kawa S, Ota M, Yoshizawa K et al (2002) HLA DRB10405- DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 122:1264-1269
68. Long EO (1999) Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 17:875-904
69. Andreevski TV, Sudomoina MA, Gusev EI et al (2002) Polymorphism A/G in position +49 of CTLA4 exon 1 in multiple sclerosis in Russians. Mol Biol 36:643-648
70. Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E et al (1998) CTLA-4 gene polymorphism is associated with predisposition to celiac disease. Gut 43:187-189
71. Orozco G, Torres B, Nunez-Roldan A et al (2004) Cytotoxic Tlymphocyteantigen-4-CT60 polymorphism in rheumatoid arthritis. Tissue Antigens 64:667-670
72. Vaidya B, Pearce S (2004) The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur J Endocrinol 150:619-626
73. Giorelli M, Livera P, Defazio G et al (2001) IFN-beta1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. J Interferon Cytokine Res 21:809-812
74. Finger EB, Bluestone JA (2002) When ligand becomes receptor - tolerance via B7 signaling on DCs. Nat Immunol 3:1056-1057
75. Kaartinen T, Lappalainen J, Haimila K et al (2007) Genetic variation in ICOS regulates mRNA levels of ICOS and splicing isoforms of CTLA4. Mol Immunol 447:1644-1651
76. Swain SL, Huston G, Tonkonogy S et al (1991) Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol 147:2991-3000
77. Catassi C, Fasano A (2010) Celiac disease diagnosis: simple rules are better than complicated algorithms. Am J Med 123:691-693
78. Sugai E, Moreno ML, Hwang HJ et al (2010) Celiac disease serology in patients with different pretest probabilities: is biopsy avoidable? World J Gastroenterol 16:3144-315